
follow us
disclaim warranti liabil
due number sourc inform servic acquisdata pti ltd servic obtain
inher hazard electron distribut may delay omiss inaccuraci inform
servic acquisdata pti ltd affili agent sale repres distributor licensor
warrant accuraci complet current merchant abil fit particular purpos
inform servic avail acquisdata pti ltd servic event acquisdata pti ltd
affili agent sale repres distributor licensor liabl license anyon els loss
injuri caus whole part conting beyond control procur compil interpret edit write
report deliv inform servic acquisdata pti ltd servic event acquisdata
pti ltd affili agent sale repres distributor licensor liabl license anyon els
decis made action taken license relianc upon inform servic consequenti
special similar damag even advis possibl damag license agre liabil
acquisdata pti ltd affili agent sale repres distributor licensor aris kind
legal claim whether contract tort otherwis way connect acquisdata pti ltd servic shall
exceed amount license paid use acquisdata pti ltd servic twelv month immedi
preced event give rise claim
second-quart sale billion increas versu
second-quart ep
adjust second-quart ep increas
acceler oper sale growth second quarter
new brunswick juli /prnewswire/ -- johnson johnson nyse today announc sale
billion second quarter increas compar second quarter
oper sale result increas posit impact currenc domest sale increas
sale increas reflect oper growth posit currenc impact
exclud net impact acquisit divestitur oper basi world-wide sale increas
domest sale increas intern sale increas
net earn dilut earn per share second quarter billion respect
second-quart net earn includ after-tax intang amort expens approxim billion
charg after-tax special item approxim billion second-quart net earn includ
after-tax intang amort expens approxim billion charg after-tax special item
approxim billion exclud after-tax intang amort expens special item adjust net
earn current quarter billion adjust dilut earn per share repres
increas respect compar period oper basi
adjust dilut earn per share also increas reconcili non-gaap financi measur
includ accompani schedul
strong second-quart result reflect double-digit growth pharmaceut busi acceler
sale momentum medic devic busi driven continu growth market lead product
strateg new launch remain focus invest innov meet need custom
deliv innov product solut posit compani deliv long-term sustain growth
said gorski chairman chief execut offic talent colleagu unit effort
address critic health consum need peopl around world
compani updat sale guidanc full-year rang billion reflect
increas expect oper growth rang partial off-set estim lower favor
impact currenc addit compani updat adjust earn guidanc full-year rang
per share reflect increas expect oper growth rang
partial off-set estim lower favor impact currenc
world-wide consum sale billion second quarter repres increas versu
prior year consist oper decreas posit impact currenc domest
sale decreas intern sale increas reflect chang oper sale
posit currenc impact exclud net impact acquisit divestitur oper basi
world-wide sale increas domest sale decreas intern sale increas
world-wide oper result exclud net impact acquisit divestitur driven over-the-
counter product includ tylenol analges digest health product intern beauti product
primarili neutrogena ogx dr ci labo partial off-set lower sale babi care product
quarter divestitur anti-dandruff shampoo brand nizor certain ketoconazole-bas shampoo
brand complet
world-wide pharmaceut sale billion second quarter repres increas
versu prior year oper increas posit impact currenc domest
sale increas intern sale increas reflect oper increas
posit currenc impact sale includ impact actelion ltd contribut world-wide
oper sale growth exclud net impact acquisit divestitur oper basi
world-wide sale increas domest sale increas intern sale increas
world-wide oper result exclud net impact acquisit divestitur driven stelara
ustekinumab biolog treatment number immune-medi inflammatori diseas zytiga
abirateron acet oral once-daili medic use combin prednison treatment
metastat castration-resist prostat cancer darzalex daratumumab treatment patient
multipl myeloma imbruvica ibrutinib oral once-daili therapi approv use treat certain b-cell
malign type blood lymph node cancer tremfya guselkumab treatment adult live
moder sever plaqu psoriasi simponi/simponi aria golimumab biolog treatment number
immune- mediat inflammatori diseas invega sustenna/xeplion/trinza/trevicta paliperidon
palmit long-act inject atyp antipsychot treatment schizophrenia adult xarelto
rivaroxaban oral anticoagul
quarter food drug administr fda approv addit indic darzalex
daratumumab combin velcad bortezomib proteasom inhibitor melphalan alkyl agent
prednison treatment patient newli diagnos multipl myeloma inelig autolog
stem cell transplant european commiss grant market author juluca dolutegravir/rilpivirin
two-drug regimen once-daili single-pil treatment supplement new drug applic
submit fda seek expand indic opsumit macitentan includ treatment adult
inoper chronic thromboembol pulmonari hypertens cteph group improv exercis
capac pulmonari vascular resist
also quarter acquisit benevir biopharm inc privately-held biopharmaceut compani
special develop oncolyt immunotherapi complet addit world-wide collabor
enter bristol-my squibb compani develop commerci factor xia inhibitor includ
prevent treatment major thrombot condit
world-wide medic devic sale billion second quarter repres increas versu
prior year consist oper increas posit currenc impact domest sale
increas intern sale increas reflect oper increas posit
currenc impact exclud net impact acquisit divestitur oper basi world-wide
sale increas domest sale increas intern sale increas
world-wide oper result exclud net impact acquisit divestitur driven acuvu
contact lens surgic product vision busi electrophysiolog product intervent solut
busi biosurg intern endocutt advanc surgeri busi wound closur product
gener surgeri busi trauma product orthopaed busi partial off-set declin
diabet busi spine product orthopaed busi
quarter compani announc accept bind offer platinum equiti acquir
lifescan busi approxim billion subject customari adjust compani also announc
receipt bind offer corpor acquir advanc steril product busi
aggreg valu approxim billion subject customari adjust addit fda approv
idesign refract studio part next gener lasik platform measur eye insid enabl
juli acquisit asset medic enterpris distribut llc privat held develop surgic
impactor technolog includ autom surgic impactor use hip replac complet
acquisdata proud host leagu estim want opportun win free
subscript join acquisdata media telecommun leagu
johnson johnson famili compani engag research develop manufactur
sale broad rang product health care field virtual countri world johnson johnson
primari interest histor current product relat human health well-b
johnson johnson incorpor state new jersey
acquisdata date busi intellig report cover develop world
report vast archiv corpor document list compani around world
abbott global diversifi healthcar compani central purpos help peopl live healthiest possibl
live offer broad portfolio market-lead product align favor long-term healthcar trend
develop develop market build strong foundat year success abbott
pois deliv top-tier growth expand margin strong cash flow increas return sharehold
januari found global biopharmaceut compani focu capabl
address world greatest health challeng stabil resourc expertis passion
discov develop bring market groundbreak scienc solv biggest health problem face
world today tomorrow
one world lead biotechnolog compani values-bas compani deepli root
scienc innov transform new idea discoveri medicin patient seriou ill
commit unlock potenti biolog patient suffer seriou ill discov
develop manufactur deliv innov human therapeut approach begin use tool like
advanc human genet unravel complex diseas understand fundament human biolog
baxter touch million live everi day product servic essenti build block healthcar
youll find baxter product therapi nearli everi floor everi depart almost everi hospit
world-wide youll find us clinic home
bristol-my squibb global biopharma compani firmli focus mission discov develop deliv
innov medicin help patient prevail seriou diseas bristol-my squibb uk aim deliv
commit patient custom employe commun environ
 compani found colonel eli lilli man commit creat high-qual medicin
meet real need centuri later passion build preced continu
pursuit make life better individu commun world around us
found year ago genentech lead biotechnolog compani discov develop
manufactur commerci medicin treat patient seriou life-threaten medic condit
compani member roch group headquart south san francisco california
unit state world largest market pharmaceut world leader biopharmaceut
research accord pharmaceut research manufactur associ phrma firm conduct
major world research develop pharmaceut hold intellectu properti right
new medicin biopharmaceut pipelin also new medicin current develop
around world approxim compound current studi unit state
region around world
peopl work biopharmaceut industri unit state recent
econom censu industri support total nearli million job across economi
includ job directli biopharmaceut compani job vendor compani broad biopharmaceut
suppli chain job creat econom activ biopharmaceut indsutri workforc
biopharmaceut industri support higher-wag job requir highly-skil educ workforc
theh administr level includ ph scientist nation scienc foundat report
biopharmaceut sector account largest singl share busi research develop
invest repres percent domest fund busi
market biolog over-the-count over-the-counter medicin gener show potenti growth
becom increasingli competit biolog account quarter new drug clinic trial await
 food drug administr approv over-the-counter market growth driven grow age popul
consum trend self-med convers drug prescript non-prescript over-the-counter statu
 market world largest free-pric market pharmaceut favor patent
regulatori environ product success larg base competit product qualiti safeti efficaci
price govern support biomed research along unparallel scientif research base
innov biotechnolog sector make market prefer home growth pharmaceut industri
innov pharmaceut industri unit state produc chemically-deriv drug develop
extens clinic trial human be anim innov reli patent form
intellectu properti right justifi invest requir bring product market patent term
year pharmaceut industri heavili depend develop new molecul replac
revenu stream older drug come expir patent term sever larg multin
produc major innov pharmaceut global come reli heavili research
perform industri partner includ smaller innov manufactur price innov pharmaceut
design recaptur expenditur
biopharmaceut industri produc medic drug deriv life form biolog includ protein
includ antibodi nucleic acid dna rna antisens oligonucleotid use therapeut vivo
diagnost purpos produc mean direct extract nativ non-engin
biolog sourc potenti controversi method produc biopharmaceut involv transgen organ
particularli plant anim genet modifi produc drug biopharmaceut industri
reli heavili research perform small compani academ institut either acquir larg
compani bring product commerci independ financ
biolog includ biosimilar includ wide rang product vaccin therapeut protein blood
blood compon tissu etc major pharmaceut compani continu diversifi biolog
acquisit biotechnolog compani in-licens product allianc biotech firm
chosen licens product joint ventur multi-national pharmaceut partner reserv
right domest market term biosimilar refer product similar properti exist biolog
gener pharmaceut industri produc copi innov pharmaceut contain activ
ingredi ident strength dosag form rout administr unit state upon patent
expir success challeng relev patent manufactur produc gener drug long
drug meet usfda regulatori requir usfda provid clearanc applic price gener
drug typic lower price innov drug mani gener drug manufactur also produc
biosimilar gener drug manufactur heavili reliant effici product method distribut chain
base volum rather price make profit regulatori system govern patent expir import
gener produc approv system biolog biosimilar
global pharmaceut market worth billion year figur expect rise billion within
three year largest drug compani control one-third market sever sale
billion year profit margin base unit state four europ
predict north south america europ japan continu account full global
pharmaceut market well centuri compani current spend one-third sale revenu
market product roughli twice spend research develop
result pressur maintain sale word inher conflict interest
legitim busi goal manufactur social medic econom need provid
public select use drug ration way particularli true drug compani main
sourc inform product effect even unit kingdom medic
profess receiv independ publicly-fund inform mani countri promot
spend pharmaceut compani time greater spend public inform health
tackl problem world assembl adopt ethic criteria medicin drug
promot dedic ration use drug howev mani observ complain guidelin
larg disregard voluntari code practic develop industri
intern feder pharmaceut manufactur associ pharma
similar conflict interest exist area drug research develop particularli area
neglect diseas privat sector domin spend million dollar year develop new drug
mass market profit imper ensur drug chosen develop like
provid high return compani invest result drug use industri world priorit
one use south mani patient would unabl pay
larg pharmaceut compani support health develop public-priv partnership number
case intern corpor foundat contribut drug product free charg help
diseas erad smithklin beecham made million commit drug albendazol
use treat lymphat filariasi elephantiasi american product provid non-tox larvicid
dupont compani contribut free cloth water filter erad guinea-worm diseas dracunculiasi
japanes nippon foundat enabl suppli blister pack contain drug need multi-
drug therapi tb suffici quantiti treat patient year countri
patient receiv treatment free charg
major contributor economi biopharmaceut sector gener high-qual job power
econom output economi accord teconomi partner llc time econom
competit nation state level recogn strongli root capac advanc
innovation-bas industri biopharmaceut industri stand lead research develop
 advanc manufactur industri
econom impact driven industri research develop enterpris
biopharmaceut sector invest rel sale manufactur industri invest
six time averag manufactur industri
sinc phrma member compani invest half trillion dollar search new
treatment cure includ estim billion alon impact spend
sector broad support biomed research rippl across economi
 biopharmaceut sector employ nearli worker support total million job across
industri help support vibrant scientif econom ecosystem vital economi
countri competit global market biopharmaceut compani put root commun across
countri help gener job across whole rang sector supplier retail person servic
job industri creat high wage requir workforc divers skill educ level
ph scientist entry-level technician support staff kind employe direct
biopharmaceut sector job earn averag salari twice averag annual
salari job
biopharmaceut sector econom output repres valu good servic produc
sector total billion unit state sector also support anoth
vendor supplier econom activ workforc total trillion
provid insight breadth industri impact form busi relationship vendor larg
small recent analysi work aggreg data innov compani across state
analysi found biopharmaceut compani spent approxim billion transact
vendor supplier state
although snapshot sector total impact find demonstr import strong
vibrant biopharmaceut industri help busi grow contribut strong local economi
vendor data analysi broken congression state legisl district view
boost state region economi
compani collabor local research institut across countryinclud clinic
research center univers medic school hospit foundationsto carri clinic trial provid patient
access potenti new treatment well creat local job
phrma program call research backyard help illustr impact trial commun
around countri twenti state report develop program releas highlight
biopharmaceut econom impact commun clinic trial
broadli biopharmaceut sector unit state spur econom activ gener job across
whole rang sector vendor supplier econom activ workforc benefit felt
far beyond individu biopharmaceut compani built upon robust foundat innovation-l
compani sustain divers large-scal suppli chain develop product distribut
treatment cure patient research teconomi provid estim econom impact
unit state state district columbia
anoth aspect econom impact medicin potenti improv product workplac
reduc absente disabl leav benefit individu patient economi whole sever
common chronic condit estim combin cost economi
trillion annual lost product exampl improv product includ
rheumatoid arthriti research integr benefit institut found high cost share rheumatoid
arthriti medic decreas adher led increas incid longer durat short-term disabl
leav research estim worker arthriti take medic direct lost product
drop percent
chronic condit research show worker diagnos diabet hypertens dyslipidemia asthma
chronic obstruct pulmonari diseas adher prescrib medicin absent seven fewer
day work use five fewer day short-term disabl compar non-adher worker
statist fact pharmaceut industri world-wide
pharmaceut industri respons develop product market medic thu
immens import global sector evid total level pharmaceut revenu world-wide reach
nearli one trillion dollar north america respons largest portion gener percent
revenu mostli due lead role pharmaceut industri mani
industri chines pharmaceut sector show highest growth rate last year
still lead pharmaceut compani come unit state europ base prescript sale
nyc-bas world second largest pharmaceut compani compani gener
billion dollar pure pharmaceut sale total revenu stood nearli billion dollar top
global player unit state johnson johnson merck novarti roch
switzerland glaxosmithklin astrazeneca unit kingdom french sanofi european big
brand patent medicin far make largest share pharmaceut revenu humira anti-
inflammatori drug gener nearli billion dollar revenu world-wide oncolog continu
lead therapeut class base revenu cancer drug made around billion dollar revenu
global major therapi class pain drug antihypertens antidiabet
industri pharmaceut sector highli depend research develop
segment pharmaceut compani invest percent revenu measur unit
state tradit stronghold pharmaceut innov new substanc introduc market trace
origin unit state steadili loss patent protect invent new drug vital
import pharmaceut industri revenu loss due patent expiri often signific
seen pfizer lipitor
acquisdata date busi intellig report cover develop world
report vast archiv corpor document list compani around world
